Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Pritzker/Vlock Family Office

Investor type Family Investment Office

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 14
Average round size
info
The average size of a deal this fund participated in
$35M
Portfolio companies 9
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.36
Exits 2
Key employees 2
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical Device
  • Software
  • Diabetes
Summary

The leading representative office of defined VC is situated in the Chicago. The venture was found in North America in United States.

Opposing the other organizations, this Pritzker/Vlock Family Office works on 4 percentage points more the average amount of lead investments. The higher amount of exits for fund were in 2017. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2015. The fund is constantly included in less than 2 investment rounds annually. Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Pritzker/Vlock Family Office, startups are often financed by Larry Bock, Andrew Mitchell, Thomas Lehrman. The meaningful sponsors for the fund in investment in the same round are PureTech Health, Virgin Group, Tom Christopoul. In the next rounds fund is usually obtained by Virgin Group, PureTech Health, Invesco.

Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Gelesis, Ubiquity Global Services, ZOZI. We can highlight the next thriving fund investment areas, such as Biotechnology, Tourism. The fund has specific favorite in a number of founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Pritzker/Vlock Family Office:
Typical Co-investors
Pritzker/Vlock Family Office is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Pritzker/Vlock Family Office:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
21 Centrale Partners Italy, Treviso, Veneto
E-Town fund -
FirstEnergy Corp. Akron, Ohio, United States
InComm Atlanta, Georgia, United States
Microfinance Enhancement Facility S.A. (MEF) -
MNC Media Investment Beijing, Beijing, China
Nilo Ventures California, San Francisco, United States
SK Telecom Ventures California, Sunnyvale, United States
Sparrow Ventures Switzerland, Zürich, Zurich
Suffolk Equity Partners Cambridge, Massachusetts, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Retia Medical

Biotechnology
Hardware
Software
$15M18 Jul 2022 Valhalla, New York, United States

Gelesis

Biotechnology
Diabetes
Health Care
Medical Device
$100M14 Jan 2022 Boston, Massachusetts, United States

Pear Therapeutics

Biotechnology
mHealth
Pharmaceutical
Software
Therapeutics
$125M03 Dec 2021 Boston, Massachusetts, United States

Iridia

Data Storage
Electronics
Semiconductor
$24M16 Mar 2021 Carlsbad, California, United States

Biorez

Biotechnology
Health Care
Medical Device
Sports
$3M14 Sep 2020 New Haven, Connecticut, United States

Shindig

Events
Video Chat
$12M01 Jan 2017 New York, New York, United States

Gelesis

Biotechnology
Diabetes
Health Care
Medical Device
$31M18 Dec 2015 Boston, Massachusetts, United States

ZOZI

E-Commerce
SaaS
Software
Tourism
Travel
$30M01 Jul 2015 San Francisco, California, United States

Gelesis

Biotechnology
Diabetes
Health Care
Medical Device
$12M16 May 2014 Boston, Massachusetts, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Pritzker/Vlock Family Office?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: